Orion Health to purchase Microsoft's HIS; will co-market HIE

Orion Health and Microsoft have signed two agreements in the field of e-health. In Asia Pacific, wholly owned subsidiary Orion Health Asia Pacific, has signed an agreement to purchase Microsoft’s hospital information system (HIS) software assets, including RIS/PACS, previously known as Amalga HIS. The two parties also have signed a memorandum of understanding outlining their intent to co-market their health information exchange (HIE) and data aggregation and analysis products—Orion Health HIE and Microsoft Amalga Unified Intelligence System—to the public and private HIE and integrated delivery network markets.

Orion will sell and market the HIS and RIS/PACS software as Orion Health HPM (Health Process Management) suite. The Microsoft HIS and RIS/PACS products were marketed in Southeast Asia under the brand name Amalga HIS and Amalga RIS/PACS until July 2010, when Microsoft discontinued development and sales of the products. Microsoft continues to develop and market Amalga Unified Intelligence System, a data aggregation and analysis platform.

Orion intends to use the acquisition of Microsoft’s HIS assets to continue expanding its engineering organization. The Thailand HIS development operation will be Orion’s fourth development center, the others being Auckland, Christchurch and Canberra, said Orion's CEO Ian McCrae. It also will provide the company with a base from which to expand its Southeast Asian organization.

The collaboration between Microsoft and Orion will enable public and private HIEs and integrated delivery networks to deploy Orion’s HIE and workflow technologies alongside the data aggregation, analytics and reporting capabilities of Microsoft Amalga Unified Intelligence System. The combination of the technologies will enable HIEs and integrated delivery networks to view and report on various individual and population patient data.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.